Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

May 15, 2018

Young Cancer Survivors Show Signs of Accelerated Aging, Study Finds

News

Adolescents and young adults who survive cancer are at higher risk of mental and physical weakness and of developing age-related diseases, such as depression and anxiety, a study reports. Other ... Read more

May 4, 2018May 4, 2018

Takeda, Nectar Plan to Test New IO Combination in non-Hodgkin Lymphoma Patients

News

Nektar Therapeutics and Takeda Pharmaceutical are working together to evaluate a new therapy combining a lead investigational compound from each company — NKTR-214 and TAK-659N — in people with blood cancers ... Read more

April 24, 2018

Phase 2 ACCEPT Trial Explores Adding Acalabrutinib to Standard DLBCL Treatment

News

A Phase 2 clinical trial, ACCEPT, is designed to determine if adding acalabrutinib to standard, first-line R-CHOP chemotherapy will benefit patients with diffuse large B-cell lymphoma (DLBCL). The trial, ongoing ... Read more

April 23, 2018

Some Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Patients Respond Well to Tazemetostat in Phase 1 Trial

News

The investigational EZH2 inhibitor tazemetostat was safe and shrank tumors in 38 percent of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma who were included in the first part of a ... Read more

April 17, 2018

New DLBCL Genetic Subtypes Offer Potential for Tailored Therapies, Researchers Say

News

An analysis of the genomic alterations and gene activity of diffuse large B-cell lymphoma (DLBCL) samples has allowed researchers to identify four genetic subtypes of the disease, which could help ... Read more

April 13, 2018April 13, 2018

Hepatitis B Infection Increases Risk of Non-Hodgkin’s Lymphoma, Research Shows

News

Chronic infection with the hepatitis B virus (HBV) is associated with a significantly higher risk of non-Hodgkin’s lymphoma, particularly for diffuse large B-cell lymphoma and follicular lymphoma, a new study revealed. ... Read more

April 10, 2018April 10, 2018

Phase 2b Trial of Betalutin in Relapsed Follicular Lymphoma Patients on Track, Nordic Says

News

A Phase 2b trial evaluating Betalutin — a tumor-targeting antibody labeled with a type of radiation — as a third-line therapy for follicular lymphoma patients will conclude a little later than ... Read more

April 4, 2018April 4, 2018

Fatigue Levels Higher, Endurance Lower for Cancer Survivors, Study Finds

News

Adults with a cancer history become fatigued more quickly and show lower endurance compared to adults who have never had cancer, according to a new study. The work, “Fatigability and ... Read more

March 23, 2018March 23, 2018

FDA Grants Orphan Drug Status to Trillium’s TTI-621 for Cutaneous T-Cell Lymphoma

News

TTI-621, an investigational molecule developed by Trillium that turns macrophages against tumor cells, was granted orphan drug status by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. ... Read more

February 28, 2018February 28, 2018

Age Alone Shouldn’t Exclude Non-Hodgkin’s Lymphoma Patients from Stem Cell Transplants, Study Finds

News

When choosing which patients are eligible for blood stem cell transplants, age is usually one of the factors weighed in. Now, a new study shows that at least for patients ... Read more